Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.

Drake LR, Pham JM, Desmond TJ, Mossine AV, Lee SJ, Kilbourn MR, Koeppe RA, Brooks AF, Scott PJH.

ACS Chem Neurosci. 2019 Aug 21;10(8):3839-3846. doi: 10.1021/acschemneuro.9b00326. Epub 2019 Aug 5.

PMID:
31339297
2.

Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases.

Narayanaswami V, Drake LR, Brooks AF, Meyer JH, Houle S, Kilbourn MR, Scott PJH, Vasdev N.

ACS Chem Neurosci. 2019 Apr 17;10(4):1867-1871. doi: 10.1021/acschemneuro.9b00081. Epub 2019 Feb 21.

PMID:
30789704
3.

Evaluation of Enzyme Substrate Radiotracers as PET/MRS Hybrid Imaging Agents.

Brooks AF, Drake LR, Shao X, Zhao A, Scott PJH, Kilbourn MR.

ACS Med Chem Lett. 2018 Oct 3;9(11):1140-1143. doi: 10.1021/acsmedchemlett.8b00402. eCollection 2018 Nov 8.

PMID:
30429959
4.

Issues in preclinical radiopharmaceutical research: Significance, relevance and reproducibility.

Kilbourn MR, Scott PJH.

Nucl Med Biol. 2018 Dec;67:52-55. doi: 10.1016/j.nucmedbio.2018.07.002. Epub 2018 Sep 3. No abstract available.

PMID:
30209016
5.

Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2.

Kilbourn MR, Koeppe RA.

ACS Chem Neurosci. 2019 Jan 16;10(1):25-29. doi: 10.1021/acschemneuro.8b00429. Epub 2018 Sep 10.

PMID:
30198706
6.

Deuterium Kinetic Isotope Effect Studies of a Potential in Vivo Metabolic Trapping Agent for Monoamine Oxidase B.

Drake LR, Brooks AF, Mufarreh AJ, Pham JM, Koeppe RA, Shao X, Scott PJH, Kilbourn MR.

ACS Chem Neurosci. 2018 Dec 19;9(12):3024-3027. doi: 10.1021/acschemneuro.8b00219. Epub 2018 Aug 17.

PMID:
30074755
7.

Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1.

Sowa AR, Brooks AF, Shao X, Henderson BD, Sherman P, Arteaga J, Stauff J, Lee AC, Koeppe RA, Scott PJH, Kilbourn MR.

ACS Chem Neurosci. 2018 Nov 21;9(11):2767-2773. doi: 10.1021/acschemneuro.8b00183. Epub 2018 May 24.

PMID:
29763549
8.

Is logP truly dead?

Kilbourn MR, Scott PJH.

Nucl Med Biol. 2017 Nov;54:41-42. doi: 10.1016/j.nucmedbio.2017.08.006. Epub 2017 Sep 9. No abstract available.

PMID:
29100559
9.

A six-year longitudinal PET study of (+)-[11C]DTBZ binding to the VMAT2 in monkey brain.

Kilbourn MR, Koeppe RA.

Nucl Med Biol. 2017 Dec;55:34-37. doi: 10.1016/j.nucmedbio.2017.08.008. Epub 2017 Sep 5.

PMID:
29031997
10.

Small Molecule PET Tracers for Transporter Imaging.

Kilbourn MR.

Semin Nucl Med. 2017 Sep;47(5):536-552. doi: 10.1053/j.semnuclmed.2017.05.005. Epub 2017 Jul 5. Review.

PMID:
28826525
11.

An updated synthesis of [11 C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor.

Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta JK, DaSilva AF, Kilbourn MR, Koeppe RA, Scott PJH, Shao X.

J Labelled Comp Radiopharm. 2017 Jun 30;60(8):375-380. doi: 10.1002/jlcr.3513. Epub 2017 May 12.

PMID:
28419528
12.

PET studies in non-human primates: Choosing drug doses.

Kilbourn MR.

Nucl Med Biol. 2017 Apr;47:1-3. doi: 10.1016/j.nucmedbio.2016.12.001. Epub 2016 Dec 9. No abstract available.

PMID:
28012346
13.

Radiochemistry, PET Imaging, and the Internet of Chemical Things.

Thompson S, Kilbourn MR, Scott PJ.

ACS Cent Sci. 2016 Aug 24;2(8):497-505. doi: 10.1021/acscentsci.6b00178. Epub 2016 Aug 16. Review.

14.

Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET.

Scott PJ, Shao X, Desmond TJ, Hockley BG, Sherman P, Quesada CA, Frey KA, Koeppe RA, Kilbourn MR, Bohnen NI.

ACS Med Chem Lett. 2016 Jun 1;7(8):746-50. doi: 10.1021/acsmedchemlett.5b00435. eCollection 2016 Aug 11.

15.

In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.

Brooks AF, Shao X, Quesada CA, Sherman P, Scott PJ, Kilbourn MR.

ACS Chem Neurosci. 2015 Dec 16;6(12):1965-71. doi: 10.1021/acschemneuro.5b00223. Epub 2015 Oct 1.

16.

Donald M. Wieland, Ph.D.

Raffel DM, Kilbourn MR, Koeppe RA.

Nucl Med Biol. 2015 Mar;42(3):213-4. doi: 10.1016/j.nucmedbio.2014.11.014. Epub 2014 Dec 9. No abstract available.

PMID:
25530209
17.

High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.

Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, Sherman P, Quesada CA, Hockley BG, Kilbourn MR, Albin RL, Frey KA, Scott PJ.

ACS Chem Neurosci. 2014 Aug 20;5(8):718-30. doi: 10.1021/cn500103u. Epub 2014 Jun 16.

18.

Carbon-11 labeled cathepsin K inhibitors: syntheses and preliminary in vivo evaluation.

Rodnick ME, Shao X, Kozloff KM, Scott PJ, Kilbourn MR.

Nucl Med Biol. 2014 May-Jun;41(5):384-9. doi: 10.1016/j.nucmedbio.2014.02.004. Epub 2014 Feb 18.

19.

In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses.

Petrou M, Frey KA, Kilbourn MR, Scott PJ, Raffel DM, Bohnen NI, Müller ML, Albin RL, Koeppe RA.

J Nucl Med. 2014 Mar;55(3):396-404. doi: 10.2967/jnumed.113.124792. Epub 2014 Jan 30.

20.

PET radioligands for the vesicular transporters for monoamines and acetylcholine.

Kilbourn MR.

J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):167-71. doi: 10.1002/jlcr.2998. Review.

21.

(-)-[(18) F]Flubatine: evaluation in rhesus monkeys and a report of the first fully automated radiosynthesis validated for clinical use.

Hockley BG, Stewart MN, Sherman P, Quesada C, Kilbourn MR, Albin RL, Scott PJ.

J Labelled Comp Radiopharm. 2013 Oct;56(12):595-9. doi: 10.1002/jlcr.3069. Epub 2013 Jul 16.

22.

Fluorine-for-hydrogen: a strategy for radiolabeling, not a replacement.

Kilbourn MR.

Nucl Med Biol. 2013 Nov;40(8):956-8. doi: 10.1016/j.nucmedbio.2013.08.006. Epub 2013 Sep 24. No abstract available.

PMID:
24074943
23.

Novel fluorine-18 PET radiotracers based on flumazenil for GABAA imaging in the brain.

Rodnick ME, Hockley BG, Sherman P, Quesada C, Battle MR, Jackson A, Linder KE, Macholl S, Trigg WJ, Kilbourn MR, Scott PJ.

Nucl Med Biol. 2013 Oct;40(7):901-5. doi: 10.1016/j.nucmedbio.2013.06.004. Epub 2013 Jul 23.

24.

Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.

Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, Brooks AF, Kilbourn MR, Albin RL, Frey KA, Scott PJ.

ACS Med Chem Lett. 2012 Sep 25;3(11):936-41. doi: 10.1021/ml300216t. eCollection 2012 Nov 8.

25.

Heterogeneity of cholinergic denervation in Parkinson's disease without dementia.

Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MR, Gilman S, Albin RL, Frey KA.

J Cereb Blood Flow Metab. 2012 Aug;32(8):1609-17. doi: 10.1038/jcbfm.2012.60. Epub 2012 May 9.

26.

Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Bohnen NI, Müller ML, Zarzhevsky N, Koeppe RA, Bogan CW, Kilbourn MR, Frey KA, Albin RL.

Brain. 2011 Aug;134(Pt 8):2358-65. doi: 10.1093/brain/awr139. Epub 2011 Jun 8.

27.

Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.

Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA.

Brain. 2011 Jun;134(Pt 6):1647-57. doi: 10.1093/brain/awr089. Epub 2011 May 9.

28.

Increased in vivo [11C]raclopride binding to brain dopamine receptors in amphetamine-treated rats.

Kilbourn MR, Domino EF.

Eur J Pharmacol. 2011 Mar 11;654(3):254-7. doi: 10.1016/j.ejphar.2011.01.008. Epub 2011 Jan 22.

PMID:
21262223
29.

Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists.

Pichika R, Jewett DM, Sherman PS, Traynor JR, Husbands SM, Woods JH, Kilbourn MR.

Nucl Med Biol. 2010 Nov;37(8):989-96. doi: 10.1016/j.nucmedbio.2010.06.002. Epub 2010 Jul 24.

30.

Rat pancreas uptake of [11C]dihydrotetrabenazine stereoisomers.

Kilbourn MR.

Nucl Med Biol. 2010 Nov;37(8):869-71. doi: 10.1016/j.nucmedbio.2010.06.001. Epub 2010 Jul 24.

PMID:
21055616
31.

Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.

Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MR, Rajan MG, Wagner HN Jr, Zaknun JJ.

Nucl Med Biol. 2010 Oct;37(7):727-40. doi: 10.1016/j.nucmedbio.2010.04.185. Review.

PMID:
20870148
32.

Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.

Albin RL, Koeppe RA, Burke JF, Giordani B, Kilbourn MR, Gilman S, Frey KA.

Arch Neurol. 2010 Apr;67(4):440-6. doi: 10.1001/archneurol.2010.34.

33.

In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations.

Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA.

Nucl Med Biol. 2010 Jan;37(1):3-8. doi: 10.1016/j.nucmedbio.2009.08.013. Epub 2009 Oct 3.

34.

(18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons.

Hefti FF, Kung HF, Kilbourn MR, Carpenter AP, Clark CM, Skovronsky DM.

PET Clin. 2010 Jan;5(1):75-82. doi: 10.1016/j.cpet.2010.02.001. Epub 2010 May 27. Review.

PMID:
27157484
35.

Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF.

J Nucl Med. 2009 Nov;50(11):1887-94. doi: 10.2967/jnumed.109.065284. Epub 2009 Oct 16.

36.

Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter.

Kilbourn MR, Hockley B, Lee L, Sherman P, Quesada C, Frey KA, Koeppe RA.

Nucl Med Biol. 2009 Jul;36(5):489-93. doi: 10.1016/j.nucmedbio.2009.02.007. Epub 2009 May 8.

37.

Signal separation and parameter estimation in noninvasive dual-tracer PET scans using reference-region approaches.

Joshi AD, Koeppe RA, Fessler JA, Kilbourn MR.

J Cereb Blood Flow Metab. 2009 Jul;29(7):1346-57. doi: 10.1038/jcbfm.2009.53. Epub 2009 Apr 29.

PMID:
19401708
38.

Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.

Albin RL, Koeppe RA, Wernette K, Zhuang W, Nichols T, Kilbourn MR, Frey KA.

Neurology. 2009 Apr 21;72(16):1390-6. doi: 10.1212/WNL.0b013e3181a187dd.

39.

Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!

Eckelman WC, Kilbourn MR, Mathis CA.

Nucl Med Biol. 2009 Apr;36(3):235-7. doi: 10.1016/j.nucmedbio.2008.12.002. No abstract available.

PMID:
19324268
40.

A simple modification of GE tracerlab FX C Pro for rapid sequential preparation of [11C]carfentanil and [11C]raclopride.

Shao X, Kilbourn MR.

Appl Radiat Isot. 2009 Apr;67(4):602-5. doi: 10.1016/j.apradiso.2008.12.013. Epub 2008 Dec 24.

PMID:
19162491
41.

Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.

Scott PJ, Hockley BG, Kung HF, Manchanda R, Zhang W, Kilbourn MR.

Appl Radiat Isot. 2009 Jan;67(1):88-94. doi: 10.1016/j.apradiso.2008.08.015. Epub 2008 Sep 7.

42.

5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands.

Li X, Jung YW, Snyder SE, Blair J, Sherman PS, Desmond T, Frey KA, Kilbourn MR.

Nucl Med Biol. 2008 Jul;35(5):549-59. doi: 10.1016/j.nucmedbio.2007.08.003. Epub 2007 Nov 26.

43.

In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.

Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, Skovronsky D, Kilbourn MR, Kung HF.

J Nucl Med. 2008 Jul;49(7):1171-6. doi: 10.2967/jnumed.108.051680. Epub 2008 Jun 13.

44.

Anesthesia increases in vivo N-([18F]fluoroethyl)piperidinyl benzilate binding to the muscarinic cholinergic receptor.

Kilbourn MR, Ma B, Butch ER, Quesada C, Sherman PS.

Nucl Med Biol. 2007 Jul;34(5):479-82.

PMID:
17591547
45.

Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use.

Scott PJ, Kilbourn MR.

Appl Radiat Isot. 2007 Dec;65(12):1359-62. Epub 2007 May 23.

PMID:
17582776
46.
47.

Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.

Kilbourn MR, Hockley B, Lee L, Hou C, Goswami R, Ponde DE, Kung MP, Kung HF.

Nucl Med Biol. 2007 Apr;34(3):233-7.

48.

Justifying the number of animals for each experiment.

Eckelman WC, Kilbourn MR, Joyal JL, Labiris R, Valliant JF.

Nucl Med Biol. 2007 Apr;34(3):229-32. No abstract available.

PMID:
17383571
49.

Imaging butyrylcholinesterase activity in Alzheimer's disease.

Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR.

Ann Neurol. 2006 Dec;60(6):746. No abstract available.

50.

Radiopharmaceutical space.

Eckelman WC, Kilbourn MR, Mathis CA.

Nucl Med Biol. 2006 Oct;33(7):829. No abstract available.

PMID:
17045161

Supplemental Content

Loading ...
Support Center